Acute leukemia after myeloma has been attributed to exposure to alkylating agents. However, leukemia is now being seen in patients receiving lenalidomide maintenance therapy. Patients with monoclonal gammopathy of undetermined significance also have an increased risk of leukemia without ever being treated.
No takes yet. Share an insight, caveat, or question.
Landgren et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: